243,427 Shares of Boston Scientific Corporation $BSX Bought by International Assets Investment Management LLC

Key Points

• International Assets Investment Management purchased 243,427 Boston Scientific shares worth approximately $10.6 million, while institutional investors collectively own 89.07% of the company.
• Boston Scientific reported quarterly earnings of $0.73 per share, in line with estimates, and revenue of $5.14 billion, slightly above expectations; revenue increased 1.4% year over year.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $61.43 price target, although several firms recently lowered targets amid cyber-incident disruptions, product weakness and reduced growth guidance.

International Assets Investment Management LLC purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 243,427 shares of the medical equipment provider's stock, valued at approximately $10,626,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd purchased a new position in Boston Scientific in the 1st quarter valued at $28,000. Cassaday & Co Wealth Management LLC acquired a new position in Boston Scientific in the 1st quarter valued at $32,000. Measured Wealth Private Client Group LLC increased its stake in Boston Scientific by 244.9% in the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider's stock valued at $34,000 after buying an additional 387 shares during the period. Kelleher Financial Advisors purchased a new position in Boston Scientific during the 2nd quarter worth $25,000. Finally, Nvwm LLC raised its position in Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider's stock worth $28,000 after buying an additional 542 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX opened at $41.93 on Friday. The company has a 50-day simple moving average of $44.78 and a 200-day simple moving average of $56.88. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $60.77 billion, a PE ratio of 17.77, a P/E/G ratio of 1.03 and a beta of 0.58. Boston Scientific Corporation has a 52-week low of $39.57 and a 52-week high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to analysts' expectations of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.75 earnings per share. Equities research analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on BSX shares. UBS Group reduced their target price on shares of Boston Scientific from $67.00 to $57.00 and set a "buy" rating for the company in a research note on Thursday. Leerink Partners dropped their price target on shares of Boston Scientific from $55.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday. Robert W. Baird raised their price objective on shares of Boston Scientific from $50.00 to $51.00 and gave the company an "outperform" rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft set a $48.00 price objective on Boston Scientific and gave the company a "buy" rating in a report on Thursday. Finally, Piper Sandler dropped their target price on Boston Scientific from $65.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.43.

Insider Transactions at Boston Scientific

In other news, Director David C. Habiger purchased 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 189,522 shares of company stock valued at $9,157,810. 0.34% of the stock is currently owned by corporate insiders.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.